<DOC>
	<DOC>NCT01528254</DOC>
	<brief_summary>The purpose of this study is to determine whether the initiation of a vildagliptin plus metformin combination regimen would result in more durable glycemic control than metformin monotherapy in treatment-naïve patients with T2DM.</brief_summary>
	<brief_title>VERIFY:A Study to Compare Combination Regimen With Vildagliptin &amp; Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes Mellitus (T2DM) diagnosed ≤ 24 months ago glycosylated hemoglobin (HbA1c) ≥6.5% and ≤7.5% at Visit 1 Treatmentnaïve. Body mass index (BMI) ≥22 and ≤40 kg/m2 at Visit 1 Pregnant or nursing (lactating) women Fasting plasma glucose (FPG) ≥ 270 mg/dL (≥ 15.0 mmol/L) Previous or current participation in any vildagliptin clinical study. History of hypersensitivity to dipeptidyl peptidase4 (DPP4) inhibitors. Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study. Donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 Diabetes Mellitus,</keyword>
	<keyword>Vildagliptin,</keyword>
	<keyword>Elderly Patients</keyword>
</DOC>